

**Review Article****Biofilm-Associated Infections on Biomedical Implants and Control Measures****Iram Liaqat<sup>1</sup>, Meer Karam Shah<sup>1</sup>, and Noor Muhammad<sup>1</sup>**<sup>1</sup>Department of Zoology, Government College University Lahore, Pakistan**ARTICLE INFO****Keywords:**

Biofilms, Biomaterials, Device-Related Infections, Implants, Nosocomial Infections

**How to Cite:**Liaqat, I., Shah, M. K., & Muhammad, N. (2025). Biofilm-Associated Infections on Biomedical Implants and Control Measures: Biofilm-Associated Infections on Biomedical Implants. *Futuristic Biotechnology*, 5(3), 20-28. <https://doi.org/10.54393/fbt.v5i3.188>**\*Corresponding Author:**Iram Liaqat  
Department of Zoology, Government College University Lahore, Pakistan  
[dr.iramliqat@gcu.edu.pk](mailto:dr.iramliqat@gcu.edu.pk)Received Date: 1<sup>st</sup> August, 2025Revised Date: 21<sup>st</sup> September, 2025Acceptance Date: 24<sup>th</sup> September, 2025Published Date: 30<sup>th</sup> September, 2025**ABSTRACT**

Biofilms are bacterial colonies that adhere to surfaces, forming protective barriers against immune responses and antibiotics, which contribute to the development of chronic infections, particularly in medical implants. This study aims to investigate the factors that influence biofilm formation on medical implants and evaluate current strategies for preventing biofilm-related infections. A review of the literature on biofilm formation mechanisms, including quorum sensing and recalcitrance, was conducted, focusing on intrinsic (e.g., quorum-sensing molecules, c-di-GMP) and extrinsic factors (e.g., temperature, surface properties). Biofilm-related infections are common in medical devices, complicating treatment and contributing to increased mortality. New strategies, including antimicrobial peptides, quorum-sensing inhibitors, and nanotechnology-based approaches, show promise in preventing biofilm formation. Surface modifications, such as antibiotic-loaded and nano-silver coatings, significantly reduce bacterial adhesion. Despite progress in biofilm prevention, further research is necessary to refine strategies for controlling implant-related infections and improving patient outcomes.

**INTRODUCTION**

Biofilms are heterogeneous bacterial colonies that adhere to surfaces and can act as a shield against the host immune system and antibiotic treatment. The colonies are embedded in a self-secreted matrix called extracellular polymeric substance (EPS), which is primarily composed of biological macromolecules and provides structural support to nearby cells, enabling the exchange of genetic material and facilitating quorum sensing [1, 2]. Approximately 80% of all human microbial infections are caused by biofilms, thereby posing a significant risk of chronic illnesses. Biofilms on medical implants are associated with severe morbidity and mortality [3]. Artificial medical implant devices, which are inserted either partially or entirely, are used to replace damaged structures and restore body functions in patients, whose

conditions would otherwise be impaired. These devices provide structural support and therapeutic benefits [4, 5]. With advancements in device technology, their demand has increased significantly; for example, in 2018, the annual growth rate of the US medical device market reached approximately \$90 billion. Approximately 0.4 to 5 million devices of various types are implanted in the US each year [6]. While these devices have improved the treatment of numerous diseases and enhanced patient well-being, they remain a global health concern due to their medical and economic implications [7]. Unfortunately, implanted devices are often associated with infection problems. Nosocomial infections (NIs), defined as infections acquired after two days of hospitalization, are frequently linked to medical devices and biofilms, accounting for




approximately 60–70% of cases. These are commonly referred to as medical device-associated infections (MDAIs). The risk of such infections is significantly higher in patients in intensive care units (ICUs), organ transplant recipients, and neonates. Various bacterial species, including both Gram-positive and Gram-negative organisms, contribute to these infections. Their capacity to form biofilms renders conventional treatment methods, such as antibiotic therapy, less effective [8, 9]. Medical device-associated infections include catheter-associated urinary tract infections (CA-UTIs), which are the most common type, accounting for 40% of nosocomial infections globally, 70% of urinary tract infections, and 20% of urinary catheter use. Venous catheters (VCs) and urinary catheters (UCs) are widely used in hospitals. The insertion of a VC can allow skin flora or environmental contaminants to reach underlying tissues, causing severe complications such as central venous catheter-related bloodstream infections (CRBSIs) in ICUs, with mortality rates ranging from 12–25% [10, 11]. After contamination of an implanted device with bacteria, biofilm formation is influenced by several factors, including the type and number of bacterial cells, which affect the rate of attachment. Additionally, fluid flow through the device, surface properties such as hydrophobicity and charge, and the duration of surface exposure before permanent attachment play important roles [12]. Once bacteria are attached and mature, factors such as flow rate, nutrient composition, temperature, and antibiotic exposure can further influence biofilm development and stability [8]. New practical approaches are being implemented to prevent biofilm infections, including the use of antimicrobial peptides and quorum-sensing inhibitors that inhibit biofilm formation [13, 14]. Additionally, surface modification of medical devices has been explored to control biofilm formation and contamination. Various modification strategies, such as antifouling, anti-adhesive coatings, and lamination, have shown promise [15]. This review aims to discuss the intrinsic and extrinsic factors affecting biofilm formation, infections caused by bacterial biofilms on medical implants, and their clinical impacts. It also examines recent control measures and strategies designed to minimize the adverse outcomes associated with these infections.

Despite significant advancements in medical implant technology, biofilm-associated infections remain a major challenge, leading to treatment failure, prolonged hospitalization, and increased mortality. While numerous studies have explored the mechanisms of biofilm formation and surface modifications to prevent bacterial adhesion, there is limited understanding of how specific intrinsic and extrinsic factors interact to influence biofilm development on different implant materials. Moreover,

most preventive strategies have been evaluated *in vitro*, with insufficient clinical correlation. This highlights the need for integrated research to identify effective, clinically translatable interventions against implant-associated biofilms.

### Biofilm Formation

Biofilm development is a complex, gradual process involving sequential stages of adhesion, aggregation, microcolony formation, maturation, and dispersal [12, 16]. During adhesion, bacteria initially attach reversibly to surfaces through electrostatic and hydrophobic interactions, followed by irreversible binding mediated by adhesins such as pili, fimbriae, and flagella, whose expression marks this stage [17]. Free-floating bacteria then aggregate via cell-to-cell adhesins and proliferate to form microcolonies, with quorum sensing activated at a threshold density to coordinate EPS production and collective behavior [18, 19]. In the maturation stage, EPS secretion, extracellular DNA release, and formation of water-filled channels support nutrient exchange and waste removal, stabilized by active gene regulation and intercellular signaling [20]. Finally, bacteria disperse from mature biofilms through proteolytic activity, alterations in intracellular signaling (e.g., c-di-GMP), or mechanical forces, enabling colonization of new surfaces [21] (Figure 1).




**Figure 1:** Various Stages of Biofilm Formation on the Surface of the Biomedical Devices

### Factors Affecting the Formation of Biofilm

Various factors, both intrinsic and extrinsic, significantly affect biofilm formation, as illustrated in Figure 2. Environmental factors and the mechanism of gene expression in bacterial cells largely influence the development of biofilm. Intrinsic Quorum-sensing (QS) molecules, C-di-GMP, and efflux pumps are intrinsic factors that regulate the formation of biofilms. Quorum Sensing (QS): It is a means of communication mediated by pheromones and extracellular molecules, which make possible the structural and developmental stability of the biofilm [22]. Quorum-sensing molecules like acyl-homoserine lactones (AHLs) induce adhesion expression by binding with receptor proteins that promote attachment and stable aggregation of bacteria [23]. They regulate the production of EPS and also coordinate activities that develop microenvironments within biofilms, where functions such as nutrient acquisition, defense

mechanisms, and active growth are carried out [24]. C-di-GMP: It is a signaling molecule having a direct relation with biofilm formation and has an inverse relation with the motility of bacteria [25]. C-di-GMP functions as a regulator. It regulates the transition from a free-floating state to a sessile lifestyle, characterized by a biofilm. Like QS molecules, it also promotes attachment and aggregation by increasing the expression of adhesion genes and other EPS matrix proteins and polysaccharide genes. A high level of c-di-GMP leads to the synthesis and secretion of EPSs, as well as the upregulation of genes involved in biofilm development and the formation of a strong matrix [26]. Efflux Pumps: As the name implies, "pump out." These pumps play a role in enhancing antibiotic resistance by effluxing antibiotics and toxic compounds [27]. Their involvement in biofilm formation lacks specific pathways; however, the long-term persistence of bacteria with reduced vulnerability to antibiotics is a potential effect of the activity and presence of efflux pumps [28]. Extrinsic Factors: Temperature, oxygen level, osmotic pressure, and hydrodynamic effects are extrinsic factors (Figure 2) that influence the physiological states of biofilm cells. Temperature: Temperature can affect both physical and physiological properties of biofilms and substrata. An optimum temperature is required for bacterial growth; any increase or decrease below this temperature has a consequential effect on the growth rate. The surface attributes of cells, such as hydrophobicity and charge, may also be influenced by incubation temperature [29]. For example, in *Listeria monocytogenes*, the hydrophobicity level of the cell surface increases with an increase in incubation temperature, which leads to biofilm formation. The rate of biofilm formation is independent of the temperature effect. The EPS matrix responds to stress, such as temperature, by forming a thick film and realigning polymers to avoid biofilm dissolution. Rise in temperature affects the viscosity of polysaccharides, resulting in a gel-like substance. Biofilms are favored at low temperatures where the polysaccharides are more uniform and stable [30]. Oxygen Concentration: Within a biofilm, a low level of oxygen mitigates metabolic activities and the growth of bacteria. Low oxygen cannot supply enough energy to sustain attachment, this triggers dispersal e.g., *Staphylococcus aureus* in the presence of oxygen minimizes biofilm formation through the sigB gene activity, whose lower expression promotes detachment while in *Staphylococcus epidermidis*, the high expression of the sigB gene activates operon icaADBC, which produce enzyme that results in the synthesis of adhesion polysaccharide leading to biofilm formation [26]. Osmotic Pressure: It is a pressure exerted on a membrane due to a concentration difference between the cell and its environment. A high level of osmotic pressure alters the

composition of the extracellular matrix and the general structure of the biofilm. Specific genes regulate the osmotic level response and can affect biofilm formation. High osmotic pressure alters adhesion gene expression in the *Aeromonas hydrophila* cell, affecting attachment and the initiation of biofilm formation [31]. Surface/Charge: A rough surface favors the initiation of biofilm. Opposite charges on surfaces favor attachment due to electrostatic interactions. Hydrodynamic Effects: High shear rates lead to an increase in the detachment of attached bacteria, while making the biofilm thinner and denser [32] (Figure 2).




**Figure 2:** Intrinsic and Extrinsic Factors Affecting Biofilm Formation

#### Device-Related Biofilm Infections

Factors involved in device-associated infections are primarily related to the biomaterial, host, and microbial origins. Host factors include tissue damage and improper integration of tissue at the junction of biomaterial, which lead to immunity loss and inflammation, respectively. These conditions initiate an infection associated with the device [33]. Biomaterials regulate biological processes, such as cell attachment and body defense, at their surfaces. Tissues are more hydrophobic, so they do not attach to polymer surfaces. Hydrophobic cells adhere well to the hydrophobic surfaces of biomaterials [34]. Microbial factors, such as the outer surface of bacterial cells, create pathogenicity, and many cells produce a glycocalyx that facilitates attachment and colonization [35]. Intravascular Catheters: Intravascular catheters are commonly used to monitor blood circulation and the administration of nutrition, medicine, and various fluids, as shown in Table 1. As the device passes through the skin, contamination with germs can result in colonization of the inner (lumen) side of the catheter, which is the second most common cause of infections associated with these devices [36]. Reports demonstrate that 82% of 2073 hospital-acquired bacteremias are linked with intravascular catheters. In the USA, at least 120,000 cases per year of septicemia are CVC-

related. Prevalent pathogens associated with catheter-related infections include *S. aureus*, which is often isolated from skin contamination at the insertion site on the catheter hub. *Candida* species attach to the catheter surface. *S. epidermidis* enhances colonization [37]. *Pseudomonas* and *Xanthomonas maltophilia* are also other agents. *E. coli* and enterococci strains rarely cause catheter-associated infections [38] (Table 1).

**Table 1:** Biofilm and Device-Related Infections

Infection Type	Common Bacterial Species	References
 Breast implants	Staphylococci > Anaerobes	[39,40]
 Contact lenses	<i>Pseudomonas aeruginosa</i> and staphylococci	[41]
 Endotracheal tubes	<i>P. aeruginosa</i> > <i>S. aureus</i> > <i>Escherichia coli</i>	[42]
 Intravascular catheters	Coagulase-negative staphylococci > Enterococci > Gram-negative bacilli > yeasts	[43]
 Orthopedic devices	Staphylococci > Gram-negative bacilli > Anaerobes	[44]
 Valves, pacemakers, grafts	Staphylococci, Streptococci	[45,46]

### Vascular Prosthesis

A prosthesis is used to replace damaged blood vessels. Vascular grafts (tubes) are used in atherosclerosis (a type of cardiovascular disease). Various agents cause infections of these grafts, such as coagulase-negative staphylococci, which are responsible for late prosthetic graft infections (Table 2) and the pseudoneurysm condition in occult graft infections [47] (Table 2).

**Table 2:** Infections and Pathogens Associated with Vascular Prosthesis

Infections / Conditions	Associated Pathogen (s)	References
Bacterial biofilm infections	<i>S. aureus</i> , coagulase-negative staphylococci, and Gram-negative bacteria	[48]
Late prosthetic graft infections	Coagulase-negative staphylococci (especially CoNS forming biofilms)	[49,50]
Occult graft infection	Coagulase-negative staphylococci	[51,52]
Anastomotic femoral pseudoaneurysm	Coagulase-negative staphylococci (e.g., <i>S. epidermidis</i> )	[53]

### Orthopedic Prosthesis

Patients who receive orthopedic devices are at risk of infections, such as septic arthritis and bacteremia [54]. These infections are a significant cause of failure of such devices. The risk of infections is increased by polymethylmethacrylate cement, which is used to fix prostheses to nearby bone, as well as by the heat released during the polymerization process, which damages tissue and ultimately increases the likelihood of infections [55].

### Endotracheal Tubes (ETTs)


Polyvinylchloride endotracheal tubes enable bacterial colonization more easily than those made of Teflon and polyurethane. These tubes are placed in the mucosal environment of the respiratory tract in patients who require mechanical ventilation. The colonization of the tube can cause pneumonia infection. According to a study by de Mendonça Bisneto et al. [56], 84% of endotracheal tubes are covered with biofilm.

### Contact Lenses

Eye infections involve multiple factors, including low tear production, a compromised cornea due to inadequate oxygen exposure, and contaminated solutions used for cleaning purposes [57]. Contact lenses serve as a substrate for colonization and also as a source of infection sites, where bacteria detach and spread to other areas. *P. aeruginosa* and *S. epidermidis* are pathogens associated with these devices [58].

### Intracardiac Prosthesis

Prosthetic valve endocarditis is a heart-related infection that can occur during the preoperative period or during surgery (Figure 3). Microorganisms gain entry during implantation. At early and late onset, the organisms found in prosthetic valve endocarditis are Coagulase-negative staphylococci and *S. aureus*, respectively [59]. *Streptococcus viridans* and enterococci are also found in late-onset cases. Treatment often needs the removal of the prosthetic device (Figure 3).



**Figure 3:** The Biofilm Life Cycle While Causing Infections

### Breast Implant Infections

The most common problem reported in 5% to 30% of patients with breast implants is the association of biofilm with the advancement of capsular contracture [60]. *S. epidermidis* and *S. aureus*, as well as anaerobes, are frequently found in cultures of breast implants. Studies show that povidone-iodine used for irrigation of the implant was the best antiseptic for removing biofilm [61].


### Control Measures

Prevention of biofilm-related infections relies on interventions that target microbial mechanisms such as adhesion, aggregation, and EPS formation. Surface modifications, including antimicrobial peptide coatings, quorum-sensing inhibitors, enzyme-based treatments, antibiotic-loaded hydroxyapatite, and nanomaterial or nano-silver coatings act by disrupting bacterial communication, attachment, and EPS synthesis, while locally delivering antibiotics to inhibit growth and reduce adhesion, thereby minimizing resistance and directly counteracting microbial colonization [62].

Antibiotic hydroxyapatite-based coatings are effective in long-term therapy because they deliver antibiotics directly to the local site, thereby controlling infections [63]. In this method, the quantity of drugs is kept low, which possibly reduces antibiotic resistance. Amoxicillin, vancomycin, cephalothin, gentamycin, and tobramycin are used in controlled-release medications. The common carrier of antibiotics is polymethylmethacrylate [64]. The controlled release of antibiotics in biodegradable carriers, such as polyglycolic acid (PGA), poly (lactic-co-glycolic acid) (PLGA), and polyethylene glycol (PEG), is highly effective in preventing infections in the long term. A biodegradable gentamycin-hydroxyapatite coating for infection prophylaxis in cementless hip prostheses, and coating PLGA with gentamycin reduces bacterial adhesion by 99%. The immersion technique is used on the surface to facilitate the absorption of antibiotics [65]. Antiseptic coatings reduce the potential for antibiotic resistance in implants [66]. Hydroxyapatite (HA), which consists of anti-

septic coatings, has been proven effective in preventing infections during implant fixation development in goats [67]. Nano-silver coating effectively controls infections by killing bacteria [68]. These particles are directly applied to the surface of implants or polymer coatings, where they eliminate bacteria through their gradual release. Silver is integrated in various devices, where nearby bacteria may be significantly influenced [69]. Silver ions disrupt cell membrane functions, protein functions, and interrupt DNA [70]. Nanomaterials are very useful in the development of modern biomedical implants and their coatings. Nanofilms, nanostructured surfaces, and nanocoatings are more beneficial than usual coatings due to their controlled drug release process [71]. Inorganic Nanocoating for Drug Delivery in Implantable Sensors and Stents. Ceramic nanoparticles promote bioactivity, adhesion, and fracture toughness to the substrate without requiring high temperatures. Diamond nanoparticles (NDs) have captured widespread attention in local drug release due to their superior physical properties and biocompatibility [72] (Figure 4).

### Control Measures



**Figure 4:** Some of the Control Measures for Biofilm-Associated Infections

### Limitations and Future Prospects

Although current strategies, such as antimicrobial coatings, quorum-sensing inhibitors, and nanomaterial-based interventions, show promise in reducing biofilm formation, their long-term efficacy and safety in clinical settings remain uncertain. Limitations include variability in implant materials, microbial diversity, and host immune responses. Future research should focus on *in vivo* studies, the development of multifunctional coatings, and the integration of advanced omics technologies to better understand biofilm dynamics, ultimately guiding the design of safer and more effective biomedical implants.

### CONCLUSION

The biofilm can be associated with the diagnosis and severity of medical infections related to the device. Infections related to biofilm increase the risk of disease

and mortality because the free-floating cells can migrate from the initial infection site to the bloodstream, potentially leading to systemic complications. However, significant advancements have been made in the prevention and treatment of biofilm-related infections, which are based on effective technologies and novel compounds. Advances in antiadhesive coatings on the surface of medical implants, which consist of nanoparticles and lipids, are used to decrease the infections related to implants. Both types of coatings play a crucial role in enhancing the performance of biomedical implant devices. The molecular apparatus is becoming increasingly advanced and accessible, enabling the physiological analysis of these small and complex biofilms. The progression in omics technologies also allows us to understand the development of biofilms. Overall, this review highlights the importance of integrated strategies for preventing and managing biofilm-related implant infections. Despite the emergence of these technologies, further efforts are needed to advance knowledge of the various microbiota compositions associated with a particular device. A successful plan of action to counter biofilm-related implant infections must be preemptive, merging advanced material design, strict aseptic procedures, and timely intervention. Sustained interdisciplinary research is crucial for advancing to more effective, safe, and clinically applicable solutions that promote implant durability and improve patient outcomes.

### Acknowledgment

All the figures were designed using BioRender software.

### Authors' Contribution

Conceptualization: IL

Methodology: IL, MKS, NM

Formal analysis: IL, NM

Writing and Drafting: IL, MKS, NM

Review and Editing: IL, MKS, NM

All authors approved the final manuscript and take responsibility for the integrity of the work.

### Conflicts of Interest

All the authors declare no conflict of interest.

### Source of Funding

The authors received no financial support for the research, authorship and/or publication of this article.

### REFERENCES

- [1] Patil M. Biofilm: A Life for Microorganisms with Basic Biofilm Principles. 2025. doi: 10.1039/9781837677047-00001.
- [2] Rath S, Fatma S, Das S. Unraveling the Multifaceted Role of Extracellular DNA (eDNA) of Biofilm in Bacterial Physiology, Biofilm Formation, and Matrixome Architecture. *Critical Reviews in Biochemistry and Molecular Biology*. 2025; May: 1-32. doi: 10.1080/10409238.2025.2497270.
- [3] Assefa M, Amare A. Biofilm-Associated Multi-Drug Resistance in Hospital-Acquired Infections: A Review. *Infection and Drug Resistance*. 2022; Jan: 5061-5068. doi: 10.2147/IDR.S379502.
- [4] Calais GB, Garcia GD, de Moura Júnior CF, Soares JD, Lona LM, Beppu MM, et al. Therapeutic Functions of Medical Implants from Various Material Categories with Integrated Biomacromolecular Systems. *Frontiers in Bioengineering and Biotechnology*. 2025; Jan 12:1509397. doi: 10.3389/fbioe.2024.1509397.
- [5] Dixit S, Gupta S, Sharma A. Surgical Devices for Biomedical Implants. In: *Additive Manufacturing for Biomedical Applications: Recent Trends and Challenges*. Singapore: Springer Nature Singapore. 2024; 195-218. doi: 10.1007/978-981-97-5456-4\_10.
- [6] Kim Y, Shin SK, Noh J. Korea: Medical Device Regulatory System. In: *Handbook of Medical Device Regulatory Affairs in Asia*. Jenny Stanford Publishing. 2018; 475-511. doi: 10.1201/9780429504396-31.
- [7] Adlhart C, Verran J, Azevedo NF, Olmez H, Keinänen-Toivola MM, Gouveia I, et al. Surface Modifications for Antimicrobial Effects in the Healthcare Setting: A Critical Overview. *Journal of Hospital Infection*. 2018; Jul 99(3): 239-249. doi: 10.1016/j.jhin.2018.01.018.
- [8] Mishra A, Aggarwal A, Khan F. Medical Device-Associated Infections Caused by Biofilm-Forming Microbial Pathogens and Controlling Strategies. *Antibiotics*. 2024; Jul 13(7): 623. doi: 10.3390/antibiotics13070623.
- [9] Khatoun Z, McTiernan CD, Suuronen EJ, Mah T-F, Alarcon EI. Bacterial Biofilm Formation on Implantable Devices and Approaches to Its Treatment and Prevention. *Heliyon*. 2018; Dec 4: e01067. doi: 10.1016/j.heliyon.2018.e01067.
- [10] Bouhrour N, Nibbering PH, Bendali F. Medical Device-Associated Biofilm Infections and Multidrug-Resistant Pathogens. *Pathogens*. 2024; May 13(5): 393. doi: 10.3390/pathogens13050393.
- [11] Alqarni MS. Catheter-Associated Urinary Tract Infection (CAUTI) in ICU Patients. *Middle East Journal of Nursing*. 2021; Feb 15(1): 25-33. doi: 10.5742/MEJN2021.93799.
- [12] Song F, Koo H, Ren D. Effects of Material Properties on Bacterial Adhesion and Biofilm Formation. *Journal of Dental Research*. 2015; Aug 94(8): 1027-1034. doi: 10.1177/0022034515587690.
- [13] Asma ST, Imre K, Morar A, Herman V, Acaroz U, Mukhtar H, et al. An Overview of Biofilm Formation-

- Combating Strategies and Mechanisms of Action of Antibiofilm Agents. *Life*. 2022; Jul 12(8): 1110. doi: 10.3390/life12081110.
- [14] Hetta HF, Ramadan YN, Rashed ZI, Alharbi AA, Alsharef S, Alkindy TT, et al. Quorum Sensing Inhibitors: An Alternative Strategy to Win the Battle Against Multidrug-Resistant (MDR) Bacteria. *Molecules*. 2024; Jul 29(15): 3466. doi: 10.3390/molecules29153466.
- [15] Moayed S, Xia W, Lundergan L, Yuan H, Xu J. Zwitterionic Polymers for Biomedical Applications: Antimicrobial and Antifouling Strategies Toward Implantable Medical Devices and Drug Delivery. *Langmuir*. 2024; Nov 40(47): 23125-23145. doi: 10.1021/acs.langmuir.4c02664.
- [16] Liaqat I, Muhammad N, Ara C, Hanif U, Andleeb S, Arshad M, et al. Bioremediation of Heavy Metals Polluted Environment and Decolourization of Black Liquor Using Microbial Biofilms. *Molecular Biology Reports*. 2023; May 50(5): 3985-3997. doi: 10.1007/s11033-023-08334-3.
- [17] Uzoma PC, Etim IIN, Okonkwo BO, Olanrele OS, Njoku DI, Kolawole SK, et al. Recent Design Approaches, Adhesion Mechanisms, and Applications of Antibacterial Surfaces. *Chemical Engineering Journal Advances*. 2023; Nov 16: 100563. doi: 10.1016/j.ceja.2023.100563.
- [18] Guzmán-Soto I, McTiernan C, González-Gómez M, Ross A, Gupta K, Suuronen EJ, et al. Mimicking Biofilm Formation and Development: Recent Progress in In Vitro and In Vivo Biofilm Models. *iScience*. 2021; May 24(5): 102443. doi: 10.1016/j.isci.2021.102443.
- [19] Damyanova T and Paunova-Krasteva T. What We Still Do not Know About Biofilms-Current Overview and Key Research Information. *Microbiology Research*. 2025; Feb 16(2): 46. doi: 10.3390/microbiolres16020046.
- [20] Liaqat F, Ansar W, Muhammad N, Tariq M, Nazir Z, Qamar HMG, et al. Development of Microbial Biofilms and Their Role in Device, Non-Device and Organ System Level Infections. *BioScientific Review*. 2025; Mar 7(1): 32-53. doi: 10.32350/bsr.72.04.
- [21] Valentini M and Filloux A. Multiple Roles of c-di-GMP Signaling in Bacterial Pathogenesis. *Annual Review of Microbiology*. 2019; Sep 73: 387-406. doi: 10.1146/annurev-micro-020518-115555.
- [22] Preda VG, Roberts L, Săndulescu O. Biofilms and Their Impact on Human Health: The Beauty and the Beast. In: *Handbook of Molecular Biotechnology*. CRC Press. 2024; 397-405. doi: 10.1201/9781003055211.
- [23] Khalid SJ, Ain Q, Khan SJ, Jalil A, Siddiqui MF, Ahmad T, et al. Targeting Acyl Homoserine Lactones (AHLs) by the Quorum Quenching Bacterial Strains to Control Biofilm Formation in *Pseudomonas aeruginosa*. *Saudi Journal of Biological Sciences*. 2021; Oct 28(10): 1673-1682. doi: 10.1016/j.sjbs.2021.10.064.
- [24] Díaz M, San Martín D, Castro M, Vera M, Guiliani N. Quorum Sensing Signaling Molecules Positively Regulate c-di-GMP Effector PelD Encoding Gene and PEL Exopolysaccharide Biosynthesis in Extremophile Bacterium *Acidithiobacillus thiooxidans*. *Genes*. 2021; Jan 12(1): 69. doi: 10.3390/genes12010069.
- [25] Kim H-S, Ham S-Y, Ryoo H-S, Kim D-H, Yun E-T, Park H-D, et al. Inhibiting Bacterial Biofilm Formation by Stimulating c-di-GMP Regulation Using Citrus Peel Extract from Jeju Island. *Science of The Total Environment*. 2023; May 872: 162180. doi: 10.1016/j.scitotenv.2023.162180.
- [26] Park S, Sauer K. Controlling Biofilm Development Through Cyclic di-GMP Signaling. In: *Pseudomonas Aeruginosa: Biology, Pathogenesis and Control Strategies*. 2022; 69-94. doi: 10.1007/978-3-031-08491-1\_3.
- [27] Zack KM, Sorenson T, Joshi SG. Types and Mechanisms of Efflux Pump Systems and the Potential of Efflux Pump Inhibitors in the Restoration of Antimicrobial Susceptibility, with a Special Reference to *Acinetobacter baumannii*. *Pathogens*. 2024 Feb; 13(3): 197. doi: 10.3390/pathogens13030197.
- [28] Hajiagha MN and Kafil HS. Efflux Pumps and Microbial Biofilm Formation. *Infection, Genetics and Evolution*. 2023; Aug 112: 105459. doi: 10.1016/j.meegid.2023.105459.
- [29] Kostoglou D, Tsaklidou P, Iliadis I, Garoufallidou N, Skarmoutsou G, Koulouris I, et al. Advanced Killing Potential of Thymol Against a Time and Temperature Optimized Attached *Listeria monocytogenes* Population in Lettuce Broth. *Biomolecules*. 2021 Mar; 11(3): 397. doi: 10.3390/biom11030397.
- [30] Alotaibi GF, Bukhari MA. Factors Influencing Bacterial Biofilm Formation and Development. *American Journal of Biomedical Science and Research*. 2021 May; 12(5): 617-626. doi: 10.34297/AJBSR.2021.12.001820.
- [31] Wang W, Cao Y, Li J, Lu S, Ge H, Pan S, et al. The Impact of Osmotic Stresses on the Biofilm Formation, Immunodetection, and Morphology of *Aeromonas hydrophila*. *Microbiological Research*. 2023 Apr; 269: 127301. doi: 10.1016/j.micres.2023.127301.
- [32] Gomes LC and Mergulhao FJ. A Selection of Platforms to Evaluate Surface Adhesion and Biofilm Formation in Controlled Hydrodynamic Conditions. *Microorganisms*. 2021 Sep; 9(9): 1993. DOI: 10.3390/microorganisms9091993.

- [33] Maimaiti Z, Li Z, Xu C, Fu J, Hao L-B, Chen J-Y, et al. Host Immune Regulation in Implant-Associated Infection (IAI): What Does the Current Evidence Provide Us to Prevent or Treat IAI? *Bioengineering*. 2023 Mar; 10(3): 356. doi: 10.3390/bioengineering10030356.
- [34] Drobota M, Ursache S, Aflori M. Surface Functionalities of Polymers for Biomaterial Applications. *Polymers*. 2022 Jun; 14(12): 2307. doi: 10.3390/polym14122307.
- [35] Kaur N and Dey P. Bacterial Exopolysaccharides as Emerging Bioactive Macromolecules: From Fundamentals to Applications. *Research in Microbiology*. 2023 May; 174(4): 104024. doi: 10.1016/j.resmic.2022.104024.
- [36] Torres CJ, Rupp ME, Cawcutt KA. Intravascular Catheter-Related Bloodstream Infections: Contemporary Issues Related to a Persistent Problem. *Infectious Disease Clinics of North America*. 2024 Dec; 38(4): 641-656. doi: 10.1016/j.idc.2024.07.002.
- [37] Moriyama K, Ando T, Kotani M, Tokumine J, Nakazawa H, Motoyasu A, et al. Risk Factors Associated with Increased Incidences of Catheter-Related Bloodstream Infection. *Medicine*. 2022 Oct; 101(40): e31160. doi:10.1097/MD.00000000000031160.
- [38] Dougnon VT, Sintondji K, Koudokpon CH, Houéto M, Agbankpé AJ, Assogba P, et al. Investigating Catheter-Related Infections in Southern Benin Hospitals: Identification, Susceptibility, and Resistance Genes of Involved Bacterial Strains. *Microorganisms*. 2023 Feb; 11(3): 617. doi: 10.3390/microorganisms11030617.
- [39] Crowe SA, Simister RL, Spence JS, Kenward PA, Van Slyke AC, Lennox P, et al. Microbial Community Compositions in Breast Implant Biofilms Associated with Contracted Capsules. *PLoS One*. 2021 Apr; 16(4): e0249261. doi: 10.1371/journal.pone.0249261.
- [40] del Pozo JL, Auba C. Role of Biofilms in Breast Implant Associated Infections and Capsular Contracture. In: *Biofilm-based Healthcare-associated Infections*. Volume II. Springer. 2014. 53-67. doi: 10.1007/978-3-319-09782-4\_5.
- [41] Urwin L, Okurowska K, Crowther G, Roy S, Garg P, Karunakaran E, et al. Corneal Infection Models: Tools to Investigate the Role of Biofilms in Bacterial Keratitis. *Cells*. 2020 Nov; 9(11): 2450. doi: 10.3390/cells9112450.
- [42] Danin P-E, Girou E, Legrand P, Louis B, Fodil R, Christov C, et al. Description and Microbiology of Endotracheal Tube Biofilm in Mechanically Ventilated Subjects. *Respiratory Care*. 2015 Jan; 60(1): 21-29. doi: 10.4187/respcare.02722.
- [43] Selby LM, Rupp ME, Cawcutt KA. Prevention of Central-Line Associated Bloodstream Infections: 2021 Update. *Infectious Disease Clinics of North America*. 2021 Dec; 35(4): 841-856. doi: 10.1016/j.idc.2021.07.004.
- [44] Beam E, Osmon D. Prosthetic Joint Infection Update. *Infectious Disease Clinics of North America*. 2018 Dec; 32(4): 843-859. doi: 10.1016/j.idc.2018.06.005.
- [45] Slouha E, Rood C, Burle VS, Al-Geizi H, Clunes LA, Kollias TF. Infective Endocarditis Following Aortic Valve Replacement: A Systematic Review. *Cureus*. 2023 Nov; 15(11): e49048. DOI: 10.7759/cureus.49048.
- [46] Klug D, Balde M, Pavin D, Hidden-Lucet F, Clementy J, Sadoul N, et al. Risk Factors Related to Infections of Implanted Pacemakers and Cardioverter-Defibrillators: Results of a Large Prospective Study. *Circulation*. 2007 Aug; 116(12): 1349-1355. doi: 10.1161/CIRCULATIONAHA.106.678664.
- [47] Costa D, Andreucci M, Ielapi N, Serraino GF, Mastroberto P, Bracale UM, et al. Infection of Vascular Prostheses: A Comprehensive Review. *Prosthesis*. 2023 Feb; 5(1): 148-166. doi: 10.3390/prosthesis5010012.
- [48] França A. The Role of Coagulase-Negative Staphylococci Biofilms on Late-Onset Sepsis: Current Challenges and Emerging Diagnostics and Therapies. *Antibiotics*. 2023 Mar; 12(3): 554. doi: 10.3390/antibiotics12030554.
- [49] Becker K, Heilmann C, Peters G. Coagulase-Negative Staphylococci. *Clinical Microbiology Reviews*. 2014 Oct; 27(4): 870-926. doi: 10.1128/CMR.00109-13.
- [50] Wagner RK, Emmelot MP, van Trikt C, Visser CE, Peters EJG, Janssen SJ, et al. Characteristics and Outcomes of Occult Infections in Presumed Aseptic Nonunions: A Retrospective Cohort Study. *Journal of Orthopaedic Trauma*. 2024 Aug; 38(8): 452-458. doi: 10.1097/BOT.0000000000002822.
- [51] Wagner RK, Emmelot MP, van Trikt C, Visser CE, Peters EJ, Janssen SJ, et al. Characteristics and Outcomes of Occult Infections in Presumed Aseptic Nonunions: A Retrospective Cohort Study. *Journal of Orthopaedic Trauma*. 2024 Aug; 38(8): 452-8. doi: 10.1097/BOT.0000000000003017.
- [52] Smet N, Bérard X, Ljungquist O, van den Hoven P, Sörelis K. Infective Native Aneurysms of the Femoropopliteal Arteries: A Systematic Review and Pooled Analysis. *Journal of Vascular Surgery*. 2025 Aug; 82(2). doi: 10.1016/j.jvs.2025.08.012.
- [53] Chung MM, Chan YC, Law Y, Cheng SW. Infectious Anastomotic Pseudoaneurysm Complicating Renal Allograft: Case Report and Review of Literature. *International Journal of Nephrology and Renovascular Disease*. 2017 Feb; 10: 55-60. doi: 10.21

- 47/IJNRD.S122725.
- [54] Laborde G, Bloise C, Karam G. Understanding Orthopaedic Infections: A Conceptual Approach. *Orthopedic Reviews*. 2024 Dec; 16: 126048. doi: 10.52965/001c.126048.
- [55] Almasri D, Dahman Y. Prosthetic Joint Infections: Biofilm Formation, Management, and the Potential of Mesoporous Bioactive Glass as a New Treatment Option. *Pharmaceutics*. 2023 May; 15(5): 1401. doi: 10.3390/pharmaceutics15051401.
- [56] de Mendonça Bisneto OI, de Carvalho Feitoza LPG, Hespanhol LC, Ferreira SB, Dagostin CS, Vieira RAMS, et al. Conventional Endotracheal Tubes Versus Polymer-Coated Tubes in Ventilator-Associated Pneumonia Development: A Systematic Review and Meta-Analysis. *Heliyon*. 2025 Dec; 11(12): e40793. doi: 10.1016/j.heliyon.2024.e40793.
- [57] Hatami H, Ghaffari Jolfayi A, Ebrahimi A, Golmohammadi S, Zangiabadian M, Nasiri MJ. Contact Lens Associated Bacterial Keratitis: Common Organisms, Antibiotic Therapy, and Global Resistance Trends: A Systematic Review. *Frontiers in Ophthalmology*. 2021 Dec; 1: 759271. doi: 10.3389/fopht.2021.759271.
- [58] Konduri R, Saiabhilash CR, Shivaji S. Biofilm-Forming Potential of Ocular Fluid *Staphylococcus Aureus* and *Staphylococcus Epidermidis* on Ex Vivo Human Corneas from Attachment to Dispersal Phase. *Microorganisms*. 2021 May; 9(6): 1124. doi: 10.3390/microorganisms9061124.
- [59] Nappi F. Advancements and Challenges in the Management of Prosthetic Valve Endocarditis: A Review. *Pathogens*. 2024 Nov; 13(12): 1039. doi: 10.3390/pathogens13121039.
- [60] Perrotta RE, Ronsivalle V, Minervini G, Cicciù M. Incidence of Long-Term Complications in Breast Implant "Prosthesis": A Systematic Review. *Prosthesis*. 2025 Mar; 7(2): 38. doi: 10.3390/prosthesis7020038.
- [61] Fernández-Ibarburu B, Díaz-Navarro M, Ibarra G, Rivera A, Hafian R, Irigoyen A, et al. Efficacy of Povidone Iodine Against Microbial Biofilms in Breast Implants with Different Textures: Results from an In Vitro Study. *Frontiers in Microbiology*. 2022; Mar 13: 868347. doi: 10.3389/fmicb.2022.868347.
- [62] Aksoy F, Karakoc Parlayan HN, Oncu Kurutas G, Yilmaz G. Antimicrobial Lock Therapy: A Strategy for Managing Catheter-Related Bacteremia. *Antibiotics*. 2025 Apr; 14(5): 461. doi: 10.3390/antibiotics14050461.
- [63] Jirofti N, Nakhaei M, Ebrahimzadeh MH, Moradi A. Review on Hydroxyapatite-Based Coatings as Antibiotic Delivery System on Bone Graft Substitution for Controlling Infection in Orthopedic Surgery. *Journal of Polymers and the Environment*. 2024 May; 32(5): 2517-2531. doi: 10.1007/s10924-023-03012-8.
- [64] Wall V, Nguyen TH, Nguyen N, Tran PA. Controlling Antibiotic Release from Polymethylmethacrylate Bone Cement. *Biomedicines*. 2021 Jan; 9(1): 26. doi: 10.3390/biomedicines9010026.
- [65] Yehia M, Farghaly U, Naguib YW. Advanced Biodegradable-Based Formulations for the Treatment of Arthritis. *Beni-Suef University Journal of Basic and Applied Sciences*. 2025 Jun; 14: 68. doi: 10.1186/s43088-025-00658-2.
- [66] Visan AI and Negut I. Coatings Based on Essential Oils for Combating Antibiotic Resistance. *Antibiotics*. 2024 July; 13: 625. doi: 10.3390/antibiotics13070625.
- [67] Rios-Pimentel FF, Méndez-González MM, García-Rocha M. A Short Review: Hydroxyapatite Coatings for Metallic Implants. *Heat Treatment and Surface Engineering*. 2023 May; 5: 2202002. doi: 10.1080/25787616.2023.2202002.
- [68] Hamed V, Bankole AA, Akinrotimi O, Ayanleye O. Silver Nanoparticles (AGNPs): A Review on Properties and Behavior of Silver at the Nanoscale Level. *International Journal of Science and Research Archive*. 2024 July; 12: 1267-1272. doi: 10.30574/ijrsra.2024.12.2.1379.
- [69] Sahoo J, Sarkhel S, Mukherjee N, Jaiswal A. Nanomaterial-Based Antimicrobial Coating for Biomedical Implants: New Age Solution for Biofilm-Associated Infections. *ACS Omega*. 2022 Dec; 7: 45962-45980. doi: 10.1021/acsomega.2c06211.
- [70] Abdulraof LAA and Naser HH. Synergistic Antimicrobial Activity of a Novel Synthetic Peptide and Silver Nanoparticles against Multidrug-Resistant *E. Coli*. *International Journal of Environmental Sciences*. 2025 Aug; 26: 828-853. doi: 10.3390/ijms26167832.
- [71] Hakim LK, Yari A, Nikparto N, Mehraban SH, Cheperli S, Asadi A, et al. The Current Applications of Nano and Biomaterials in Drug Delivery of Dental Implants. *BMC Oral Health*. 2024 Jan; 24: 126. doi: 10.1186/s12903-024-03911-9.
- [72] Xue Y, Feng X, Roberts SC, Chen X. Diamond and Carbon Nanostructures for Biomedical Applications. *Functional Diamond*. 2022 Dec; 1: 221-242. doi: 10.1080/26941112.2021.2013716.